Tarsus Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. Co.'s primary product candidate, TP-03, is an investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, which is referred to as Demodex blepharitis. Co. is developing product candidates to address targeted diseases with unmet medical needs, which include TP-03 for the potential treatment of Meibomian Gland Disease, TP-04 for the potential treatment of rosacea, and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.